Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Johanna Joyce and colleagues show that tumour-associated macrophages protect breast tumour cells from cell death mediated by various chemotherapeutic agents.
Two papers inNature Geneticsshow that the isocitrate dehydrogenases IDH1 and IDH2 are mutated in two subtypes of the cancer-prone enchondromatosis syndrome.
Two studies reported inNature have identified a mutation in microphthalmia-associated transcription factor (MITF) that predisposes to familial melanoma, as well as to sporadic melanoma and renal cell carcinoma.
The treatment of patients with refractory non-small-cell lung cancer with a low-dose DNA methyltransferase inhibitor and a histone deacetylase inhibitor shows promise for a subset of patients.
Using a mouse model of chemically induced skin tumours, Cédric Blanpain and colleagues have uncovered an autocrine role for vascular endothelial growth factor signalling in cancer stem cells.
Genomic analysis combined with functional screening has identified an extracellular non-membrane bound form of the ephrin receptor EPHA7 as a tumour suppressor in follicular lymphoma that could be exploited therapeutically.
ThisCellpaper shows that an interaction between the SH2 and kinase domains of BCR–ABL is necessary for kinase activation; inhibition of this interface prevents leukaemogenesis in mice and can restore sensitivity to tyrosine kinase inhibitors.
